JPMorgan raised the firm’s price target on Replimune (REPL) to $18 from $16 and keeps an Overweight rating on the shares. The firm updated models in the smid-cap biotechnology group.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune Group’s Promising Milestones and Strong Financial Position Drive Buy Rating
- Replimune price target raised to $22 from $21 at H.C. Wainwright
- Navigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global Risks
- Replimune price target raised to $19 from $16 at Wedbush
- Replimune price target raised to $21 from $18 at Leerink